Study on the Diagnostic Value of Serum Tumor Markers CEA, CA153, and CYFRA21 in Invasive Breast Cancer

Objective: To explore the diagnostic value of serum tumor markers CEA, AFP, CA199, CA125, CA153, CYFRA21, CA724, and NSE in invasive breast cancer. Methods: A total of 314 patients with invasive breast cancer from Baoding First Central Hospital between January 2021 and December 2022, and 31 patients with benign breast diseases (including mastitis, breast fibroadenoma, breast adenosis, adenoma of the breast, benign phyllodes tumor of the breast, and intraductal papilloma) were randomly selected as the control group. The levels of CEA, AFP, CA199, CA125, CA153, CYFRA21, CA724, and NSE were measured using electrochemiluminescence. Results: The serum concentrations of CEA, CA153, and CYFRA21 showed significant statistical differences between the invasive breast cancer group and the benign breast disease group (P < 0.01). ROC curve analysis revealed that CA153 had the highest sensitivity for diagnosing invasive breast cancer, while CEA had the highest specificity, at 84.4% and 77.4%, respectively. When multiple tumor markers were used for the diagnosis of invasive breast cancer, the combination of CEA and CA153 showed the highest specificity at 90.3%, while the combination of CEA and CYFRA21 had the highest sensitivity at 88.2%. The combined detection of CEA, CYFRA21, and CA153 had the largest area under the curve (AUC) on the ROC curve, at 0.802, indicating that the combination of these three markers provided the best diagnostic performance for invasive breast cancer. Conclusion: CEA, CA153, and CYFRA21 can be used for the diagnosis of invasive breast cancer, and the combined detection of these three markers offers the best diagnostic efficacy for invasive breast cancer.